☆ 4.8 Article

Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity

FRONTIERS IN IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing

Adnan Qureshi et al.

Summary: Reinfection with SARS-CoV-2 is rare but has been associated with mortality. The severity of reinfection appears to be milder, with fewer cases of severe illness compared to primary infection. Risk factors for reinfection include asthma and nicotine dependence/tobacco use.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Review Medicine, Research & Experimental

SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment

Dapeng Li et al.

Summary: This article summarizes representative SARS-CoV-2 neutralizing antibodies that have been reported and discusses prospects and challenges for the development of the next generation of COVID-19 preventive or therapeutic antibodies.

ANNUAL REVIEW OF MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

Immunity to SARS-CoV-2 induced by infection or vaccination

Xaquin Castro Dopico et al.

Summary: Adaptive immune responses are crucial for viral clearance and protection against re-infection, including SARS-CoV-2. The rapid characterization of the immune response to the virus during the first 20 months of the pandemic has provided a detailed understanding. The development and global rollout of effective COVID-19 vaccines have made a significant impact, although challenges remain in terms of equal access.

JOURNAL OF INTERNAL MEDICINE (2022)

Add to Collection

Review Immunology

The germinal centre B cell response to SARS-CoV-2

Brian J. Laidlaw et al.

Summary: The GC response is crucial in establishing durable and broad immunity against SARS-CoV-2, with emerging evidence suggesting new approaches to modulate GC response and long-term immune responses induced by vaccines. Importantly, GC B cell responses persist for at least 6 months in some individuals following SARS-CoV-2 vaccination.

NATURE REVIEWS IMMUNOLOGY (2022)

Add to Collection

Article Immunology

A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity

Vincent Legros et al.

Summary: The study investigated the neutralizing antibody response in serum samples from 140 confirmed SARS-CoV-2 infections, finding that antibody titers correlated with disease severity and anti-spike IgG levels. Post-recovery, patients' nAb activity declined more rapidly compared to individuals infected with other coronaviruses, and previous infection by human coronaviruses did not generate protective nAbs against SARS-CoV-2. Additionally, the D614G mutation in the spike protein did not lead to neutralization escape.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Cell Biology

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin et al.

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Letter Immunology

Severe Reinfection With South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant 501Y.V2

Noemie Zucman et al.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Chang Kyung Kang et al.

Summary: The memory T-cell response to SARS-CoV-2 persists for up to 8 months post-symptom onset, with potentially stronger responses in patients with severe illness compared to those with mild or asymptomatic disease. Further investigations are necessary to assess the longevity and protective effect of this immune response against reinfection.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Christian Holm Hansen et al.

Summary: The study investigated the protection against SARS-CoV-2 reinfection, with results showing an 80.5% protection rate for individuals previously infected. Even in the population aged 65 years and older, the protection rate against reinfection reached 47.1%, with no significant differences observed by gender or time since infection.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Victoria Jane Hall et al.

Summary: This study investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. It found that individuals with a previous history of SARS-CoV-2 infection had an 84% lower risk of reinfection, with a median protective effect lasting for 7 months following primary infection.

LANCET (2021)

Add to Collection

Review Immunology

An update: the emerging evidence of complement involvement in COVID-19

Qin Li et al.

Summary: The current outbreak of COVID-19 has global impacts, affecting various organs and leading to tissue injury and multiorgan failure due to abnormal activation of host immune response. Targeting the complement system could be a potential treatment option for organ damage in COVID-19 patients.

MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Joseph E. Ebinger et al.

Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Laith J. Abu-Raddad et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection

Gabriele Anichini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation

Sisi Kang et al.

Summary: This study isolated and analyzed 32 N protein-specific monoclonal antibodies from a COVID-19 convalescent patient, shedding light on the response to the N protein. The complex structure of the mAb with the highest binding affinity revealed changes in epitopes and regulation of the antigen, affecting the N protein-induced complement hyperactivation.

NATURE COMMUNICATIONS (2021)

Add to Collection

Letter Immunology

Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection

Pyoeng Gyun Choe et al.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Biology

COVID-19 optimal vaccination policies: A modeling study on efficacy, natural and vaccine-induced immunity responses

Manuel Adrian Acuna-Zegarra et al.

Summary: After over a year into the COVID-19 pandemic, global deaths have surpassed two million, and while vaccines have shown progress, cases continue to rise with uncertainties around vaccine-induced and natural immunity. With vaccine supply shortages leading to delays in some countries, logistical, economic, and political factors present challenges in developing vaccination policies.

MATHEMATICAL BIOSCIENCES (2021)

Add to Collection

Article Multidisciplinary Sciences

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

Rachel Yamin et al.

Summary: Monoclonal antibodies with optimized Fc domains show superior potency in preventing and treating COVID-19 in animal disease models, reducing the dose required for protection against SARS-CoV-2 challenge and for treating pre-infected animals. Selective engagement of activating Fc receptors results in improved efficacy, highlighting the importance of Fc receptor pathways in driving antibody-mediated antiviral immunity. These findings have implications for the development of Fc-engineered monoclonal antibodies with optimal Fc-effector function against COVID-19.

NATURE (2021)

Add to Collection

Letter Biochemistry & Molecular Biology

SARS-CoV-2 variants of concern are emerging in India

Jasdeep Singh et al.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery

Chengqian Feng et al.

Summary: The study found that SARS-CoV-2 specific immune response can persist to some extent up to 1 year after recovery from COVID-19, with serum neutralizing capacity decreasing but remaining stable. Viral-specific cellular immune protection persists between 6 months and 12 months after recovery.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Immunology

Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset

Tiandan Xiang et al.

Summary: One year after infection, most recovered patients still have detectable SARS-CoV-2-specific IgG antibodies, but only a minority have neutralizing activity, especially when facing specific mutated variants. This highlights the importance of vaccinations for individuals who have had a natural infection to protect against emerging variants.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

Alyson M. Cavanaugh et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2 P.2 Lineage Associated with Reinfection Case, Brazil, June October 2020

Paola Cristina Resende et al.

Summary: A 37-year-old healthcare worker in northeastern Brazil experienced two clinical episodes of COVID-19 caused by the B.1.1.33 and emerging P.2 lineages. The findings not only suggest a reinfection case but also the geographic dissemination of the emerging Brazil clade P.2.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Clinical Characteristics and Outcomes of COVID-19 Cohort Patients in Daegu Metropolitan City Outbreak in 2020

Shin-Woo Kim et al.

Summary: The COVID-19 outbreak in Daegu, Korea was controlled by the end of March 2020. A retrospective, multicenter cohort study conducted on 7,057 laboratory-confirmed patients revealed that 77% were asymptomatic to mild. Key risk factors for 28-day mortality included age, need for O-2 supply, fever, and underlying health conditions like diabetes and cancer.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Zunyou Wu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Multidisciplinary Sciences

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp et al.

SCIENCE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

Add to Collection

Article Infectious Diseases

Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity

Chang Kyung Kang et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors

Chang Kyung Kang et al.

JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Medicine, Research & Experimental

SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia

Wei Chen et al.

BIOMEDICINE & PHARMACOTHERAPY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Bette Korber et al.

CELL (2020)

Add to Collection

Letter Infectious Diseases

Viral dynamics in mild and severe cases of COVID-19

Yang Liu et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

Naoki Kaneko et al.

CELL (2020)

Add to Collection

Article Medicine, Research & Experimental

Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

Panagiotis Skendros et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Article Multidisciplinary Sciences

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients

Jan C. Holter et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Letter Immunology

Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients

Pyoeng Gyun Choe et al.

EMERGING INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Baoqing Sun et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

Article Immunology

A Sample-Sparing Multiplexed ADCP Assay

Audrey L. Butler et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Review Immunology

Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses

Matthew Zirui Tay et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Immunology

An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages

Tae Hyun Kang et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Immunology

IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions

Chang-Han Lee et al.

NATURE IMMUNOLOGY (2017)

Add to Collection

Article Hematology

Altered IL-7Rα expression with aging and the potential implications of IL-7 therapy on CD8+ T-cell immune responses

HR Kim et al.

BLOOD (2006)

Add to Collection

Article Immunology

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

VC Huber et al.

JOURNAL OF IMMUNOLOGY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.